Mr PORTER (Pearce—Minister for Industry, Science and Technology) (14:18): I thank the member for his question. It was I think 30 years ago that the cutting-edge researchers at the University of Wisconsin first experimented on mRNA technology in mice, and it took 30 years for the first mRNA technology and vaccines to be put in the arms of human beings in the context of COVID-19. The single first vaccine that have been used on human beings and that used mRNA technology was used in the context of the COVID-19 pandemic—very, very recently. This is absolutely cutting-edge technology. The proposition contained in the question from the Leader of the Opposition—that somehow it would be reasonable to put to the Australian people that it would be possible that right now Australia would be manufacturing mRNA vaccines—is just not a reasonable proposition. The idea that— The SPEAKER: The Leader of the Opposition on a point of order? Mr Albanese: Far be it from me to interrupt the minister attacking his predecessor, but the question went to— The SPEAKER: When you rise on a point of order, you need to state what the point of order is. We all know what the rules are. Points of order are not a chance to debate the matter. I give enormous tolerance to the leaders of both parties, but you simply need to just— Mr Albanese: I appreciate that. The SPEAKER: I want you to appreciate it more. Mr Albanese: That's just not possible! The SPEAKER: You have the call. Come to the point of order. It might help if you state what it is. Mr Albanese: The point of order is on relevance. The question went to the government's own announcement, 10 months ago, that it was looking at manufacturing facilities. The SPEAKER: The Leader of the Opposition will resume his seat. The Minister for Industry, Science and Technology has the call. Mr PORTER: Of course, Australia has got this sort of capability and capacity. Choosing the right path to realise that capability and capacity is the job of a responsible government. To ensure that Australians get the best, most sustainable deal, the deal that provides for a 10-year end-to-end capability that can not merely produce a domestic market that's scalable from zero vaccines to 25 million plus in a short period of time for a cutting-edge technology but is also able to provide scalable production for export markets and a breadth of goods using this cutting-edge technology—including therapeutics, potentially, for cancer treatments, for which mRNA had its genesis, and for cardiovascular disease—means you have to have a thorough, thoughtful process. That process means having submissions for fully costed proposals for end-to-end onshore population-scale mRNA capability. It means ensuring the proposals show demonstrated— (Time expired)